KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Short-term Investments: 2009-2024

Historic Short-term Investments for Novavax (NVAX) over the last 12 years, with Dec 2024 value amounting to $392.9 million.

  • Novavax's Short-term Investments rose 47.34% to $494.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $494.9 million, marking a year-over-year increase of 47.34%. This contributed to the annual value of $392.9 million for FY2024, which is N/A change from last year.
  • Per Novavax's latest filing, its Short-term Investments stood at $392.9 million for FY2024, which was up 149.22% from $157.6 million recorded in FY2020.
  • Novavax's 5-year Short-term Investments high stood at $392.9 million for FY2024, and its period low was $157.6 million during FY2020.
  • Over the past 1 years, Novavax's median Short-term Investments value was $392.9 million (recorded in 2024), while the average stood at $392.9 million.